290 related articles for article (PubMed ID: 24089324)
21. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis.
Martin-Oliva D; Aguilar-Quesada R; O'valle F; Muñoz-Gámez JA; Martínez-Romero R; García Del Moral R; Ruiz de Almodóvar JM; Villuendas R; Piris MA; Oliver FJ
Cancer Res; 2006 Jun; 66(11):5744-56. PubMed ID: 16740713
[TBL] [Abstract][Full Text] [Related]
22. Poly adenosine diphosphate-ribose polymerase inhibitor PJ34 abolishes systemic proinflammatory responses to thoracic aortic ischemia and reperfusion.
Black JH; Casey PJ; Albadawi H; Cambria RP; Watkins MT
J Am Coll Surg; 2006 Jul; 203(1):44-53. PubMed ID: 16798486
[TBL] [Abstract][Full Text] [Related]
23. Poly(ADP-ribose) polymerase-1 modulation of in vivo response of brain hypoxia-inducible factor-1 to hypoxia/reoxygenation is mediated by nitric oxide and factor inhibiting HIF.
Martínez-Romero R; Cañuelo A; Martínez-Lara E; Javier Oliver F; Cárdenas S; Siles E
J Neurochem; 2009 Oct; 111(1):150-9. PubMed ID: 19656264
[TBL] [Abstract][Full Text] [Related]
24. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
25. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.
Kauppinen TM
Neurochem Int; 2007 Jun; 50(7-8):954-8. PubMed ID: 17222947
[TBL] [Abstract][Full Text] [Related]
26. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
Komjáti K; Besson VC; Szabó C
Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
[TBL] [Abstract][Full Text] [Related]
27. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
28. Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator.
Laudisi F; Sambucci M; Pioli C
Endocr Metab Immune Disord Drug Targets; 2011 Dec; 11(4):326-33. PubMed ID: 21476963
[TBL] [Abstract][Full Text] [Related]
29. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Virág L
Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
[TBL] [Abstract][Full Text] [Related]
30. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
Virág L; Szabó C
Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
[TBL] [Abstract][Full Text] [Related]
31. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
32. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
de la Lastra CA; Villegas I; Sánchez-Fidalgo S
Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-ribose) polymerase 1 inhibition protects against low shear stress induced inflammation.
Qin WD; Wei SJ; Wang XP; Wang J; Wang WK; Liu F; Gong L; Yan F; Zhang Y; Zhang M
Biochim Biophys Acta; 2013 Jan; 1833(1):59-68. PubMed ID: 23085506
[TBL] [Abstract][Full Text] [Related]
34. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.
Luo X; Kraus WL
Genes Dev; 2012 Mar; 26(5):417-32. PubMed ID: 22391446
[TBL] [Abstract][Full Text] [Related]
35. Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1.
Tao R; Kim SH; Honbo N; Karliner JS; Alano CC
J Cardiovasc Pharmacol; 2010 Dec; 56(6):659-68. PubMed ID: 20881608
[TBL] [Abstract][Full Text] [Related]
36. Poly (ADP-ribose) polymerases (PARPs) 1-3 regulate astrocyte activation.
Phulwani NK; Kielian T
J Neurochem; 2008 Jul; 106(2):578-90. PubMed ID: 18410506
[TBL] [Abstract][Full Text] [Related]
37. Novel modulators of poly(ADP-ribose) polymerase.
Szabo C; Pacher P; Swanson RA
Trends Pharmacol Sci; 2006 Dec; 27(12):626-30. PubMed ID: 17055069
[TBL] [Abstract][Full Text] [Related]
38. Poly (ADP-ribose) polymerase inhibition protects against myocardial ischaemia/reperfusion injury via suppressing mitophagy.
Cao S; Sun Y; Wang W; Wang B; Zhang Q; Pan C; Yuan Q; Xu F; Wei S; Chen Y
J Cell Mol Med; 2019 Oct; 23(10):6897-6906. PubMed ID: 31379115
[TBL] [Abstract][Full Text] [Related]
39. PARP mediates structural alterations in diabetic cardiomyopathy.
Chiu J; Farhangkhoee H; Xu BY; Chen S; George B; Chakrabarti S
J Mol Cell Cardiol; 2008 Sep; 45(3):385-93. PubMed ID: 18657544
[TBL] [Abstract][Full Text] [Related]
40. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
Decker P; Muller S
Curr Pharm Biotechnol; 2002 Sep; 3(3):275-83. PubMed ID: 12164482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
